Pancreatic Cancer Research

ResearcherThe Royal Melbourne HospitalActive in the last 2 years

Peter Gibbs

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0003-1423-4484; OpenAlex author ID A5047478386, A5126195998. Sources: OpenAlex.

Their work

Papers
20 (first author 2, last author 5)
Trials
0
Grants
0
Labs led
1
Collaborators
44
Papers, trials and grants by year

2015: 1 paper · 2016: none · 2017: none · 2018: none · 2019: 3 papers · 2020: none · 2021: 1 paper · 2022: 4 papers · 2023: 4 papers · 2024: 3 papers · 2025: 2 papers · 2026: 2 papers

Papers 20

  1. Timeliness of Care and Treatment Patterns for Pancreatic Cancer in Victoria, Australia: Comparison With Optimal Care Pathways Targets. Last author DOI 10.1111/ans.70705↗
  2. Systematic Review and Meta-Analysis of Current and Novel Approaches in the Management of Borderline Resectable and Locally Advanced Pancreatic Cancer. Co-author DOI 10.3390/cancers18071139↗
  3. Skeletal muscle and visceral fat density are predictive imaging biomarkers for overall survival in patients with pancreatic adenocarcinoma: A retrospective mul… Co-author DOI 10.1016/j.suronc.2025.102251↗
  4. Exploring the association between Cultural and Linguistic Diversity (CALD) on treatment and outcomes in pancreatic cancer: an analysis of PURPLE real-world reg… Last author DOI 10.1186/s12889-025-23925-4↗
  5. Impact of neoadjuvant FOLFIRINOX over upfront resection in borderline resectable pancreatic cancer-an international, multicentre, real-world analysis. Co-author DOI 10.1016/j.esmorw.2023.100022↗
  6. Early onset pancreatic cancer-exploring contemporary treatment and outcomes using real-world data. Co-author DOI 10.1038/s41416-024-02619-5↗
  7. Evolution of Liquid Biopsies for Detecting Pancreatic Cancer. First author DOI 10.3390/cancers16193335↗
  8. Current state of radiomic research in pancreatic cancer: focusing on study design and reproducibility of findings. Co-author DOI 10.1007/s00330-023-09653-6↗
  9. S100 family proteins are linked to organoid morphology and EMT in pancreatic cancer. Co-author DOI 10.1038/s41418-023-01126-z↗
  10. Correction to: S100 family proteins are linked to organoid morphology and EMT in pancreatic cancer. Co-author DOI 10.1038/s41418-023-01151-y↗
  11. Use and outcomes from neoadjuvant chemotherapy in borderline resectable pancreatic ductal adenocarcinoma in an Australasian population. Last author DOI 10.1111/ajco.13807↗
  12. Impact of first-line FOLFIRINOX versus Gemcitabine/Nab-Paclitaxel chemotherapy on survival in advanced pancreatic cancer: Evidence from the prospective interna… Co-author DOI 10.1016/j.ejca.2022.06.042↗
  13. Treatment and outcomes of unresectable and metastatic pancreatic cancer treated in public and private Australian hospitals. Co-author DOI 10.1111/ajco.13721↗
  14. Real-world staging computed tomography scanning technique and important reporting discrepancies in pancreatic ductal adenocarcinoma. Co-author DOI 10.1111/ans.17787↗
  15. Use and outcomes of chemotherapy for metastatic pancreatic cancer in Australia. Co-author DOI 10.1111/imj.15094↗
  16. The Diverse Applications of Pancreatic Ductal Adenocarcinoma Organoids. Co-author DOI 10.3390/cancers13194979↗
  17. Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer. Last author DOI 10.1093/annonc/mdz200↗
  18. Inflammation, Biomarkers and Immuno-Oncology Pathways in Pancreatic Cancer. First author DOI 10.3390/jpm9020020↗
  19. Clinical Applications of Circulating Tumour DNA in Pancreatic Adenocarcinoma. Last author DOI 10.3390/jpm9030037↗
  20. Phase II trial of selective internal radiation therapy and systemic chemotherapy for liver-predominant metastases from pancreatic adenocarcinoma. Co-author DOI 10.1186/s12885-015-1822-8↗

Closest collaborators

The 25 strongest of 44 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Belinda Lee · 17 shared papers, 2019–2026 · strength 3.13
  2. Benjamin N. J. Thomson · 10 shared papers, 2019–2026 · strength 1.66
  3. Mehrdad Nikfarjam · 7 shared papers, 2019–2026 · strength 1.10
  4. Benjamin P. T. Loveday · 5 shared papers, 2022–2026 · strength 0.93
  5. Hyun Soo Ko · 4 shared papers, 2022–2025 · strength 0.79
  6. Sam Banks · 3 shared papers, 2024–2026 · strength 0.60
  7. Adnan M. Nagrial · 4 shared papers, 2019–2024 · strength 0.51
  8. Shehara Ramyalini Mendis · 3 shared papers, 2022–2025 · strength 0.51
  9. Matthew Burge · 4 shared papers, 2019–2024 · strength 0.49
  10. Yat Hang To · 3 shared papers, 2022–2024 · strength 0.47
  11. Adrian M. Fox · 3 shared papers, 2023–2024 · strength 0.45
  12. Ronnie Ren Jie Low · 3 shared papers, 2021–2023 · strength 0.42
  13. Sean Michael Grimmond · 3 shared papers, 2021–2023 · strength 0.42
  14. Tracy L. Putoczki · 3 shared papers, 2021–2023 · strength 0.42
  15. Ryan B. Munnings · 1 shared paper, 2024 · strength 0.36
  16. Kelvin Le · 1 shared paper, 2026 · strength 0.36
  17. Prasad D. Cooray · 3 shared papers, 2019–2023 · strength 0.35
  18. Margaret Lee · 2 shared papers, 2022–2025 · strength 0.33
  19. Silja Schrader · 1 shared paper, 2026 · strength 0.26
  20. Jon D. Emery · 1 shared paper, 2026 · strength 0.26
  21. James Alex Malcolm · 1 shared paper, 2023 · strength 0.24
  22. Sebastian Nowak · 1 shared paper, 2025 · strength 0.24
  23. Julian Alexander Luetkens · 1 shared paper, 2025 · strength 0.24
  24. Maike Theis · 1 shared paper, 2025 · strength 0.24
  25. Niall Christopher Tebbutt · 2 shared papers, 2019–2023 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.